STUDY QUESTION: Is a peroxisome proliferator-activated receptor-γ coactivator 1α (PGC-1α)-mediated pathway involved in the development of endometriosis?
Introduction
Endometriosis is a common gynecological disease characterized by the presence and growth of endometrium-like tissues at extrauterine sites. Morbidity levels in endometriosis reach ∼6-10% in reproductive-age females, and endometriosis causes symptoms such as chronic pelvic pain, dysmenorrhea and infertility, which severely impair patients' health and quality of life (Giudice and Kao, 2004) . Although recent studies have investigated the histological origin of endometriosis, the precise etiology of endometriosis remains poorly understood. Currently, hormonal therapy and surgical removal of endometriotic lesions are the established treatments for endometriosis, but hormonal therapy produces adverse side effects, and surgical intervention can be followed by a high recurrence rate and infertility (Vercellini et al., 2008; Seracchioli et al., 2009) . Thus, it is crucial to develop endometriosis treatments that are more effective and produce fewer harmful effects than current treatments, and this requires comprehensive elucidation of the molecular pathological properties of endometriotic tissues.
Accumulating evidence indicates that local estrogen production plays key roles in endometriosis pathogenesis (Bulun, 2009) . Disease symptoms and endometriotic lesions are frequently relieved after menopause, and thus endometriosis is considered an estrogendependent disease. Moreover, the enzyme aromatase, which catalyzes the final step in estrogen biosynthesis, is more highly expressed in endometriotic tissues than in the endometrium (Huhtinen et al., 2012) , and estrogen, produced by the abnormally elevated aromatase, promotes the growth of endometriotic tissue (Bulun, 2009; Rizner, 2009; Huhtinen et al., 2012; Colette et al., 2013) . Previously, we revealed that peroxisome proliferator-activated receptor-γ (PPARγ ) coactivator-1α (PGC-1α) contributes to aberrant local estrogen production through aromatase in ovarian endometrioma (OE), but not in endometrium with endometriosis or normal endometrium (NE) without endometriosis (Suganuma et al., 2014) . These findings suggest that PGC-1α represents a promising candidate for novel targeted therapies for endometriosis.
PGC-1α is a transcription coactivator that interacts with diverse transcription factors involved in various biological responses, including adaptive thermogenesis, mitochondrial biogenesis, oxidative metabolism and steroidogenesis (Liang and Ward, 2006; Cormio et al., 2009; Yazawa et al., 2010) . For example, in brown adipose tissue, PGC-1α, induced by cold exposure, co-activates PPARγ to stimulate adipocyte differentiation (Puigserver et al., 1998) ; in ovarian granulosa cells, PGC-1α regulates progesterone production by acting as a coactivator of steroidogenic factor-1 and liver receptor homolog-1 (Yazawa et al., 2010) ; and in skeletal muscle cells, PGC-1α affects glucose intake by downregulating the expression of insulin-sensitive glucose transporter type 4 (Miura et al., 2003) . Thus, PGC-1α is differentially expressed in distinct tissues and functions as a coactivator that interacts with tissue-specific transcription factors. We previously found that PGC-1α expression was aberrantly elevated in OE and correlated with aromatase tissue localization (Suganuma et al., 2014) . However, the functional consequences of PGC-1α interaction with other transcription factors in endometriosis remain unclear.
Estrogen can potentially act as not only as a proliferative factor but also a proinflammatory and antiapoptotic factor in endometriotic stromal cells (SCs) (Bukulmez et al., 2008; Reis et al., 2013) . Interleukin (IL)-6 and IL-8, which are inflammatory cytokines secreted by macrophages and immune cells, are highly expressed in local tissues and the peritoneal fluid of patients with endometriosis (Bergqvist et al., 2001; Harada et al., 2001; Darai et al., 2003) , and these cytokines, in turn, promote the proliferation of endometriotic SCs (Iwabe et al., 2000) . Moreover, a concomitant overexpression of antiapoptotic factors in SCs is associated with aberrant survival of the cells and thus with their ability to invade the peritoneum and establish an endometriotic implant (Reis et al., 2013) , and these effects appear to be exacerbated in endometriosis. Here, we investigated whether PGC-1α affects endometriotic SC proliferation and examined how PGC-1α influences estrogen action, inflammation and apoptosis in endometriosis. We propose that PGC-1α could serve as a molecular target in endometriosis treatments involving the use of compounds that produce transcriptionally inhibitory effects on PGC-1α.
Materials and Methods

Patients and samples
OE specimens were obtained from 23 reproductive-age females (mean age, 36.9 years; range, 24-47 years) who underwent surgery for OE. The endometriosis stages were III (n = 7) and IV (n = 16) according to the American Society for Reproductive Medicine classification of endometriosis (American Society for Reproductive Medicine, 1997) . NE samples were obtained from 10 reproductive-age females (mean age, 35.9 years; range, 24-46 years) who underwent surgery for uterine leiomyoma. None of the patients had received hormone treatment for at least 3 months before surgery. All specimens were at the proliferative phase of the regular menstrual cycle when the surgery was performed. This study was approved by the Institutional Review Board of Kyoto Prefectural University of Medicine (ERB-C-606), and informed consent was obtained from each patient. 
Antibodies
All antibodies used in this study are listed in Table I . The antibody specificity was evaluated by western blotting with the respective positive control. Specificity of the anti-retinoid X receptor (RXR) α antibody used for immunohistochemistry was also evaluated by comparison of the staining and co-localization with two antibodies raised against different epitopes of the investigated protein ( Supplementary Fig. S1 ).
Cell isolation and culture
Cells were isolated as described previously (Yamanaka et al., 2012; Suganuma et al., 2014; Takaoka et al., 2018) . Briefly, tissues were minced, digested with 2.5% type I collagenase (Sigma-Aldrich, St. Louis, MO, USA) and 15 IU/ml DNase I (Takara Shuzo, Kyoto, Japan) and filtered through a nylon cell strainer. The filtrate was centrifuged with lymphocyte separation solution (Nacalai Tesque, Kyoto, Japan) to remove lymphocytes. Purity (>95%) of all 23 OESCs preparations was confirmed by positive staining for CD10 (Agilent, Santa Clara, CA, USA). Also, the preparation was shown not to be contaminated with granulosa cells and follicular cells by negative staining for inhibin A (Abcam, Cambridge, UK) and anti-Müllerian hormone (Proteintech, Tokyo, Japan; Supplementary Fig. S2 ). After the cultured primary SCs became sub-confluent, they were collected by treatment with 0.1% trypsin and resuspended in phenol red-free Dulbecco's modified Eagle's medium (DMEM) (Nacalai Tesque) supplemented with 10% dextrancoated, charcoal-treated fetal bovine serum (FBS) and 1% penicillin and 100 μg/ml streptomycin; the SCs were then cultured in 6 cm plates for protein extraction, 24-well plates for luciferase assays, 6-well plates for RNA extraction or 96-well plates for WST-8 assays. 
Plasmids and reagents
The plasmid pGL3-ERRE, the pGL3-aromatase-promoter plasmid containing promoters I.3-II (−329/+284; exon I.3 start site designated as +1) and the pSG5-PGC-1α expression vector were used as described (Suganuma et al., 2014) ; pSG5-emptyvector and pGL3-basic reporter plasmids were used as controls. HX531, an RXR antagonist, was purchased from Tocris Bioscience (Bristol, UK).
Transfection
All transfections were performed on sub-confluent cells. Cells were transfected with 0.2 μg each of reporter plasmid (pGL3-basic, pGL3-ERRE, pGL3-aromatase-promoter I.3-II) and expression plasmid (pSG5-empty, pSG5-PGC-1α) for luciferase assays, 0.1 μg of expression plasmid (pSG5-empty, pSG5-PGC-1α) for cell proliferation assays, 2.5 μg of expression plasmid (pSG5-empty, pSG5-PGC-1α) for RNA extraction and 3.75 μg of expression plasmid (pSG5-empty, pSG5-PGC-1α) for western blotting analysis. Lipofectamine LTX (Life Technologies, Carlsbad, CA, USA) was used for transfection as per the manufacturer's protocol. Cells were cultured in phenol red-free DMEM supplemented with 10% dextran-coated, charcoal-treated FBS and then used for analyses after 48-72 h incubation.
Luciferase assay
Luciferase assays were performed using the ONE-Glo TM EX Luciferase Assay System and a GloMax 20/20 Luminometer (Promega, Madison, WI, USA) as per the manufacturer's protocol.
Exon I-specific RT-PCR
Aromatase exon I-specific RT-PCR analysis was performed as described (Kinoshita and Chen, 2003) . Briefly, RT-PCR was performed using each forward primer of aromatase exons I.3, PII and II with a reverse primer of exon II to amplify exons I.3, PII and II. GAPDH primers were used as an internal control. Primer sequences are listed in Supplementary Table SI. RT-PCR was conducted using Premix Taq (Takara Shuzo) and a GeneAmp PCR 9700 (Applied Biosystems, Foster City, CA, USA) and the following thermal cycling conditions: stage 1, 10 s at 98 • C; stage 2, 35 cycles of 10 s of melting at 98 • C, followed by DNA synthesis for 30 s at 54 • C and 60 s at 72 • C. PCR products were electrophoresed on 1.5% agarose/Tris-borate-EDTA gels, and the integrated band intensities in ethidium bromide-stained gels were analyzed using a ChemiDoc XRS+ system (Bio-Rad, Hercules, CA, USA).
Cell proliferation and cytotoxicity assays
OESCs and NESCs were cultured and maintained in 96-well plates for 24 h and then transfected with pSG5-empty/PGC-1α. After HX531 treatment for 24-72 h, viable cells were quantified using a modified WST-8 assay (Nacalai Tesque); 10 μL of the WST-8 reagent (2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2, 4-disulfophenyl)-2H-tetrazolium, monosodium salt) was added to each well and the plates were incubated for 2 h at 37 • C, after which 450/655 nm absorbance was measured using a microplate reader. Compound cytotoxicity was examined using the CytoTox-Fluor cytotoxicity assay (Promega). Fluorescence was measured at 485Ex/520Em by using a SpectraMax M2e instrument (Molecular Devices, San Jose, CA, USA) after 24-72 h treatment with/without HX531.
mRNA extraction, cDNA preparation and real-time PCR analysis of human tissue
Total RNA was extracted from excised OE and NE tissues by using a RNeasy Mini Kit (QIAGEN, Hilden, Germany) as per manufacturer instructions, and RNA concentrations were determined by measuring the ultraviolet (260/280 nm) absorption with a Nano Drop spectrophotometer (Thermo Fisher Scientific, Waltham, MA, USA). Next, 1 μg of each RNA sample was used to prepare cDNA by using a ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan) and a GeneAmp PCR 9700, and the cDNA was used for real-time PCR and exon Ispecific RT-PCR. Real-time PCR was performed using a Step One RealTime PCR system (Applied Biosystems) and this protocol: stage 1, 60 s at 95 • C; stage 2, 40 cycles of 3 s of melting at 95 • C, followed by DNA synthesis for 30 s at 60 • C. Quantitative real-time PCR was conducted using a Power SYBR Green kit. The PCR mixture (20 μL) contained 1 μL of cDNA samples prepared from tissues and cells and 0.3 μM of each primer for the target genes. The sequences of the primers used are listed in Supplementary Table SI . Threshold cycle (Ct) values were calculated using the Ct method (Yamanaka et al., 2012) .
Western blotting
Cells in primary culture were washed twice in PBS and lysed in radioimmunoprecipitation assay buffer (Nacalai Tesque). Cell lysates (20 μg) were heated in sodium dodecyl sulphate (SDS) sample buffer (125 mM Tris-HCl, pH 6.8, 4% SDS, 25% glycerol, 10% 2-mercaptoethanol, Real-time PCR analysis of PGC-1α knockdown and (C) the effect of the knockdown on OESC (n = 5)/NESC (n = 4) proliferation; cells were transfected with control or PGC-1α siRNA (siPGC-1α). Results are expressed as percentages of control values (Cont) and presented as means ± SEMs. Statistical analysis was performed using Student's t-test and repeated measures ANOVA, followed by multiple comparisons using Dunnett's procedure. * P < 0.05, * * P < 0.01 versus control.
0.05 mM phenylmethanesulfonyl fluoride and 0.004% bromophenol blue), separated on 10% e-PAGEL gels as per the manufacturer's protocol (Atto Corp, Tokyo, Japan) and transferred onto ImmunoBlot ® polyvinylidene difluoride (PVDF) membranes (Bio-Rad). The membranes were blocked in PVDF Blocking Reagent (Toyobo) for 1 h and then incubated with antibodies (rabbit anti-Phospho-IκBα (#2859) and rabbit anti-GAPDH (#2118), Cell Signaling, Danvers, MA, USA) at 4 • C overnight. After washing, the membranes were incubated with the secondary antibody (anti-rabbit IgG, HRP-linked antibody (#7074), Cell Signaling) for 1 h at room temperature. The staining signal was developed using Chemi-Lumi One Super (Nacalai Tesque) and analyzed using a ChemiDoc XRS+ system with Image Lab software (Bio-Rad).
RNA interference
PGC-1α-specific siRNA (s21395) and negative control siRNA (siNeg) (control #1) targeting known genes were purchased from Thermo Fisher Scientific (Silencer Select siRNAs ® ). Cells were transfected with siRNAs by using Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) as per the manufacturer's protocol and used for experiments after 72 h. After incubation, the cells were processed for each analysis.
Immunohistochemistry
OE and NE specimens were immunohistochemically stained as described (Mori et al., 2011) . OE tissue was pathologically H-scores of RXRα immunoreactivity in NE (n = 8)/OE (n = 9) specimens. HX531 effect on the proliferation of (E) OESCs (n = 5) and (F) NESCs (n = 5) analyzed using WST-8 assays. Results are expressed as percentages of control values (Cont) and presented as means ± SEMs. Statistical analysis was performed using Student's t-test and repeated measures ANOVA, followed by multiple comparisons using Dunnett's procedure. * P < 0.05, * * P < 0.01 versus control.
diagnosed with the presence of endometriotic SC by CD10 staining and the hemosiderin deposit by haematoxylin-eosin staining ( Supplementary Fig. S3 ). Anti-RXRα antibody was used at 200 μg/ml. The immunostaining intensities of OE and NE were evaluated using the Histogram score (H-score), a semiquantitative index calculated as described previously (Yamanaka et al., 2012 assay results, PGC-1α overexpression induced mRNA expression and HX531 effect were analyzed using repeated measures ANOVA, followed by multiple comparisons using Dunnett's procedure. All analyses were performed using Prism software v7 (Graph Pad Software Inc., San Diego, CA, USA). Data are presented as mean ± standard error of the mean (SEM). All assays for each experiment were performed in triplicate. P < 0.05 was considered statistically significant.
Results
PGC-1α promoted proliferation of OESCs but not NESCs
To examine whether PGC-1α affects the proliferation of endometriotic SCs, we performed WST-8 cell proliferation assays. PGC-1α Statistical analysis was performed using Student's t-test and repeated measures ANOVA, followed by multiple comparisons using Dunnett's procedure. * P < 0.05, * * P < 0.01 versus control.
overexpression caused a time-dependent and statistically significant increase in proliferation in OESCs but not NESCs (Fig. 1A) . In addition, all individual experiments confirmed promotion of significant cell proliferation by PGC-1α overexpression ( Supplementary Fig. S4 ). We also conducted loss-of-function experiments; real-time PCR analysis confirmed siRNA-mediated PGC-1α knockdown (Fig. 1B) , and WST-8 assay results showed that the knockdown inhibited the proliferation of OESCs but not NESCs (Fig. 1C) .
HX531, an RXRα antagonist, inhibited PGC-1α-induced transcriptional activity in OESCs
Next, to identify compounds that might exert transcriptionally inhibitory effects on PGC-1α, we performed luciferase reporter assays. Previously, our chromatin immunoprecipitation results showed that PGC-1α was recruited to a region containing the nuclear receptor half-site 5 -AGGTCA-3 (ERRE) (Suganuma et al., 2014) . Here, we confirmed that PGC-1α induced the luciferase transcriptional activity of ERRE in OESCs and then screened various compounds; we found that 72 h treatment with the RXRα antagonist HX531 inhibited PGC-1α-induced ERRE activity ( Fig. 2A) . PPARγ agonist and antagonist did not show an inhibitory effect on PGC-1α-induced ERRE activity ( Supplementary Fig. S5 ). CytoTox-Fluor assay results showed that HX531 was not toxic to OESCs (Fig. 2B ). Immunohistochemical analysis of OE and NE specimens further revealed high RXRα expression in both the nucleus and the cytoplasm in OE specimens (Fig. 2C) , and RXRα immunostaining intensity was markedly higher in OESCs than NESCs (Fig. 2D) . Notably, HX531 suppressed PGC-1α-induced OESC proliferation but not NESC proliferation. (Fig. 2E and  F) . Immunohistochemistry of peritoneal endometriotic explants and deep infiltrating endometriosis showed positive immunoreaction of SCs to PGC-1α ( Supplementary Fig. S6 ).
PGC-1α enhanced aromatase expression and promoter activity in OESCs
We previously demonstrated that PGC-1α enhanced aromatase expression and promoter activity in OESCs (Suganuma et al., 2014) . Accordingly, PGC-1α increased aromatase mRNA levels (Fig. 3A) , and this induced expression was markedly suppressed by HX531 (Fig. 3A) . Next, we performed aromatase exon I-specific RT-PCR. The aromatase gene contains nine translated exons (II-X) and multiple untranslated exon Is. In endometriotic tissues, PI.3 and PII are mainly used to regulate aromatase mRNA expression (Zeitoun et al., 1999) . In accord with our report (Suganuma et al., 2014) , we confirmed that the transcripts of the aromatase promoters PI.3, P.II and exon II were induced by PGC-1α, and HX531 downregulated PGC-1α-stimulated PI.3-II aromatase promoter transcripts in OESCs (Fig. 3B) . Moreover, as reported previously, we did not detect mRNA expression of aromatase exon Is or II in EESCs and NESCs, regardless of PGC-1α expression (Suganuma et al., 2014) . Furthermore, the results of loss-of-function experiments showed that siRNA-mediated PGC-1α knockdown substantially reduced aromatase-coding mRNA levels in cells (Fig. 3C ).
PGC-1α enhanced expression of estrogen receptor β and SGK1 in OESCs
To understand the regulation of PGC-1α-induced estrogen receptor (ER) signaling, we examined the expression of ERα and ERβ and of serum and glucocorticoid-regulated kinase (SGK1), a potent downstream transcriptional regulator of ERβ that helps exacerbate Statistical analysis was performed using Student's t-test and repeated measures ANOVA, followed by multiple comparisons using Dunnett's procedure. * P < 0.05 versus control, * * P < 0.01 versus control.
endometriosis. Real-time PCR results showed that PGC-1α increased ERβ and SGK1 expression in OESCs (Fig. 4B and C) but reduced ERα expression (Fig. 4A) .
PGC-1α elevated inflammatory cytokine expression in OESCs
We performed real-time PCR analysis to assess how PGC-1α affects inflammatory cytokines in endometriosis. PGC-1α elevated IL-6 and IL-8 mRNA levels in OESCs, and HX531 attenuated these responses ( Fig. 5A and B) . The nuclear factor-kappa B (NF-κB) and inhibitor kappa B (IκB) complex could help elevate IL-6/IL-8 levels in endometriosis (Kim et al., 2012) ; IκB phosphorylation results in NF-κB activation and this would lead to IL-6/IL-8 elevation (Gonzalez-Ramos et al., 2010) . Here, western blotting revealed that in OESCs, PGC-1α induced IκB phosphorylation under tumor necrosis factor (TNF)-α stimulation, and HX531 inhibited this induced phosphorylation (Fig. 5C) . Moreover, siRNA-mediated PGC-1α knockdown decreased IL-6/IL-8 mRNA levels in OESCs (Fig. 5D ).
PGC-1α upregulated IAPs in OESCs
Lastly, examination of PGC-1α effects on inhibitor of apoptosis proteins (IAPs; antiapoptotic factors) in OESCs revealed that PGC-1α overexpression increased survivin and X-linked inhibitor of apoptosis protein (XIAP) mRNA levels ( Fig. 6A and B) . Intriguingly, HX531 markedly attenuated PGC-1α-induced expression of survivin but not XIAP ( Fig. 6A and B) . However, siRNA-mediated PGC-1α knockdown reduced the expression of both antiapoptotic factors in OESCs (Fig. 6C ).
Discussion
We demonstrated here for the first time that PGC-1α stimulated the proliferation of OESCs but not NESCs. We also showed that PGC-1α induced ERβ and SGK1 expression in OESCs as well as aromatase, as we previously reported (Suganuma et al., 2014) . Our results further indicated that PGC-1α upregulated the inflammatory cytokines IL-6 and IL-8 and promoted apoptosis resistance in OESCs. Moreover, we identified a compound that produced transcriptionally inhibitory effects on PGC-1α in OESCs; HX531, an RXR antagonist, inhibited PGC-1α-induced cell proliferation and PGC-1α-elevated expression of aromatase, IL-6/IL-8 and survivin in OESCs. Thus, we propose that PGC-1α could play critical roles in endometriosis development and might represent a novel molecular target for endometriosis treatment. PGC-1α, a transcriptional coactivator that interacts with diverse transcription factors, can potentially function in numerous biological responses, including adaptive thermogenesis, mitochondrial biogenesis and glucose and fatty acid metabolism. PGC-1α is highly expressed in tissues that are enriched in mitochondria and where oxidative metabolism is active, such as brown adipose tissue, heart and skeletal muscle (Puigserver et al., 1998) . PGC-1α is expressed at lower levels in breast and colon cancer tissues than in normal tissues (Jiang et al., 2003; Feilchenfeldt et al., 2004; Watkins et al., 2004) , but is highly expressed in uterine endometrial cancer tissues (Ren et al., 2015) . Previously, we showed that PGC-1α expression was higher in OE than NE by using specimens from patients with or without endometriosis, and the expression was significantly correlated with aromatase expression in OE (Suganuma et al., 2014) . Here, cell proliferation assays revealed that PGC-1α promoted the proliferation of OESCs but not NESCs, whereas PGC-1α knockdown reduced the proliferation. All individual experiments confirmed promotion of significant cell proliferation by PGC-1α overexpression (Supplementary Fig. S4 ). These findings indicate that PGC-1α potentially represents a molecular target for endometriosis therapy.
We next sought to identify compounds that could control PGC-1α function in endometriosis. To our knowledge, no ligands for PGC-1α are currently available. PGC-1α interacts with PPARγ in a ligand-independent manner (Puigserver et al., 1998) . PPARγ binds to peroxisome proliferator response elements (PPREs), which are located in promoters and contain two copies of the core motif 5 -AGGTCA-3 . Interestingly, our previous chromatin immunoprecipitation analysis revealed PGC-1α recruitment to the nuclear half-site ERRE, 5 -AGGTCA-3 , in OESCs. Thus, we used the ERRE site with a luciferase reporter system to identify compounds that exhibit agonistic/antagonistic activities toward PGC-1α in OESCs. We initially examined a PPARγ agonist and antagonist, pioglitazone and GW9662; the use of these compounds is widely accepted because several lines of evidence have indicated their clinical or preclinical efficacy in diabetes treatment and reduction of macrovascular events in diabetes patients (Dormandy et al., 2005) . However, pioglitazone and GW9662 showed no effects on transcription ( Supplementary Fig. S5 ). We next focused on compounds that affect RXRα, because PPARs form heterodimers with RXRα, which leads to binding of the PPRE site and transcriptional coactivation by PGC-1α (Mangelsdorf et al., 1995; Giguere, 1999; Delerive et al., 2002; Gronemeyer et al., 2004) . Luciferase reporter assay results showed that among the compounds tested here, HX531 produced transcriptionally inhibitory effects on PGC-1α in OESCs. Moreover, immunohistochemical analysis revealed that RXRα expression was higher in OE than NE, and, intriguingly, the subcellular localization of RXRα in OE specimens was mostly consistent with that of PGC-1α. Previous evidence has also indicated overlapping tissue distribution of PGC-1α and RXRα (Chambon, 1996; Puigserver et al., 1998) . However, further investigation is required to elucidate PGC-1α interaction with RXRα in endometriosis. Here, HX531 suppressed PGC-1α-induced proliferation of OESCs, but not NESCs, which suggests that the PGC-1α-RXRα axis could play critical roles in promoting endometriosis.
Estrogen production plays a key role in endometriosis (Kitawaki et al., 1997; Bulun et al., 2005; Huhtinen et al., 2012) . Previously, we reported that aromatase is more highly expressed in endometriotic tissue than in NE and PGC-1α stimulated aromatase activity (Kitawaki et al., 1997 , Suganuma et al., 2014 . In contrast, some studies reported that aromatase was not expressed in endometriotic tissues (Colette et al., 2009 studies might be due to differences in specificity of antibody or the biopsy specimens investigated. The aromatase gene contains nine translated exons (II-X) and multiple copies of untranslated exon I. Each exon I is regulated by its own promoter located immediately upstream of exon I, and each promoter is regulated through distinct mechanisms, which leads to tissue-specific aromatase expression. Our exon I-specific RT-PCR confirmed previous findings indicating that PI.3-II of the aromatase gene represents the main promoter in OESCs (Zeitoun et al., 1999) . HX531 attenuated PGC-1α-induced elevation of expression and PI.3-II transcripts of aromatase in OESCs, and the levels of aromatase-coding mRNA were also markedly decreased in PGC-1α-knockdown cells. These results suggest that PGC-1α represents a key therapeutic target for controlling estrogen production by regulating aromatase in endometriosis.
Locally upregulated estrogen binds to ERs in endometriosis and thus stimulates estrogen-dependent growth (Bulun, 2009) . ERβ expression was shown to be higher in OE than NE, and signaling through ERβ was found to play critical roles in endometriosis establishment and maintenance (Xue et al., 2007; Juhasz-Boss et al., 2011; Han et al., 2012) . Here, PGC-1α altered expression patterns to cause higher expression of ERβ than ERα in OESCs. ERβ was previously shown to directly bind to ERα promoter and repress ERα expression, leading to a state of progesterone resistance in endometriosis (Bulun et al., 2012) . However, it remains unknown whether PGC-1α directly interacts with ER isoforms and affects progesterone resistance. Bulun et al. (2012) recently found that SGK1 is a transcriptional target in ERβ-mediated regulation and this helps promote endometriotic SC survival. Interestingly, our study showed that PGC-1α also increased SGK1 expression in OE. Collectively, these findings suggest that PGC-1α accelerates ERβ-mediated signaling in endometriosis.
IL-6 and IL-8 are representative inflammatory cytokines that are highly elevated in the peritoneal fluid of patients with endometriosis and in OESCs (Harada et al., 1997) . Harada et al. have also demonstrated that TNF-α upregulates IL-6 and IL-8 production through NF-κB activation in OESCs (Sakamoto et al., 2003; Yamauchi et al., 2004; Takai et al., 2013) . Recently, activation of the NF-κB and IκB complex was shown to potentially help elevate IL-6/IL-8 levels in endometriosis (Kim et al., 2012) . Thus, previous evidence indicates that NF-kB activity in endometriotic tissues stimulates inflammation and cell proliferation (Kim et al., 2011; Zhang, et al., 2011) . Here, we found that PGC-1α upregulated IL-6/IL-8 expression in OESCs, and HX531 attenuated this elevated expression, and further that PGC-1α activated IκB phosphorylation and HX531 suppressed this response in OESCs. These results suggest that PGC-1α could exert inflammatory effects by regulating the NF-κB and IκB complex in endometriosis, which disagrees with the only previous related report showing that in skeletal muscle cells PGC-1α inhibited IL-6 expression in the presence of TNF-α. Further investigation is necessary to clarify the underlying mechanism because no study to date has shown PGC-1α association with the NF-κB and IκB complex in endometriosis.
Apoptosis-programmed cell death-plays a critical role in maintaining tissue homeostasis by eliminating excess cells. Endometriotic cells show diminished spontaneous apoptosis and resistance to apoptotic stimuli such as cytokines (Dmowski et al., 2001; Nishida et al., 2005) , and impaired apoptotic mechanisms contribute to the abnormal survival of these cells in ectopic sites. The inability of endometriotic cells to undergo normal apoptosis is associated with their increased expression of antiapoptotic factors. Previous studies have demonstrated that IAP expression is higher in OESCs than NESCs, and that survivin, an IAP-family representative, plays a critical role in the apoptosis susceptibility of endometrial SCs (Taniguchi et al., 2009; Uegaki et al., 2015) . We found that PGC-1α enhanced survivin and XIAP mRNA levels in OESCs, and further that HX531 attenuated PGC-1α-induced expression of survivin but not XIAP in OESCs. To our knowledge, this is the first report of a relationship between PGC-1α and IAPs in endometriosis. Previously, in skeletal muscle cells, PGC-1α was shown to enhance hypoxia-inducing factor (HIF)-1α-dependent gene expression by increasing mitochondrial oxygen consumption (O'Hagan et al., 2009) . Interestingly, the HIFbinding site (hypoxia-responsive element) is located in the survivin promoter, and hypoxia has recently been shown to play critical roles in endometriosis development and progression (Lee and Tsai, 2017) . Thus, the crosstalk between PGC-1α and apoptotic factors under hypoxia warrants investigation.
As mentioned above, PGC-1α plays an important role in various biological responses. PGC-1α is differentially expressed in distinct tissues and functions as a coactivator interacting with tissue-specific factors. Because RXRα interacts with other nuclear receptors, inhibiting RXRα functions for treatment of endometriosis might inhibit other unexpected functions. Therefore, targeting PGC-1α directly is more likely to be beneficial for treatment of endometriosis. However, it is also important to inhibit PGC-1α functions locally and not systemically in order to avoid major side effects. In this study, we used NESC as control samples from women with uterine leiomyoma. Ideally, the control group would comprise age-matched fertile women with no uterine pathology. To minimize the effect of the leiomyoma on adjacent endometrial SC, patients with subserosal uterine leiomyoma were chosen because subserosal leiomyoma induced less inflammatory effects on endometrium than submucosal and intramural leiomyoma (Miura et al., 2006) . We also used OESC to investigate the function of PGC-1α and not peritoneal endometriotic explants, which are more common than OE. We also confirmed that PGC-1α was highly expressed in peritoneal and deep infiltrating endometriotic specimens by immunostaining ( Supplementary Fig. S6 ). We believe that these results could be applicable to peritoneal and deep infiltrating endometriosis. Further investigation is needed to confirm our findings.
In conclusion, we demonstrated that PGC-1α could play critical roles in cell proliferation, estrogen signaling, inflammation and antiapoptosis in endometriosis. Interestingly, HX531, a recognized RXRα antagonist, was identified as a compound that exerts transcriptionally inhibitory effects on PGC-1α; HX531 suppressed PGC-1α-induced cell proliferation and expression of aromatase, IL-6 and IL-8. Moreover, survivin, a key molecule in apoptosis resistance in endometriosis, might be regulated by PGC-1α. Thus, the PGC-1α-mediated pathway represents a potential target in molecular therapy for endometriosis.
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